戴维医疗(300314) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥137,101,263.14, a decrease of 3.21% compared to the same period last year, and a total revenue of ¥402,925,721.56 for the year-to-date, down 12.21% year-on-year[2] - Net profit attributable to shareholders for Q3 2024 was ¥16,781,726.70, down 45.90% year-on-year, with a year-to-date net profit of ¥63,307,872.06, a decrease of 48.44%[2] - The basic earnings per share for Q3 2024 was ¥0.0583, a decline of 45.87%, and the diluted earnings per share was also ¥0.0583, reflecting the same percentage decrease[2] - Total operating revenue for Q3 2024 was CNY 402,925,721.56, a decrease of 12.2% compared to CNY 458,961,630.27 in the same period last year[14] - Net profit for Q3 2024 was CNY 63,307,872.06, a decline of 48.3% from CNY 122,795,311.05 in Q3 2023[15] - The comprehensive income total for Q3 2024 was CNY 63,614,662.42, down from CNY 122,795,311.05 in the previous year[15] - Basic earnings per share for Q3 2024 were 0.2198, down from 0.4264 in the same period last year[16] Cash Flow - The net cash flow from operating activities for Q3 2024 was ¥14,030,641.34, down 79.94% compared to the previous year[5] - Cash inflow from operating activities totaled 410,191,271.93 yuan, a decrease of 17.9% compared to 499,907,726.86 yuan in the previous year[17] - Net cash flow from operating activities was 14,030,641.34 yuan, significantly lower than 69,934,687.29 yuan in the prior year, reflecting a decline of 80%[17] - The net cash flow from investing activities was -¥265,669,366.09, a decrease of 491.37% compared to the previous year, primarily due to a reduction in net investment recoveries[7] - Cash outflow from investing activities amounted to 990,882,919.06 yuan, an increase from 928,015,021.61 yuan in the previous year[18] - Net cash flow from investing activities was -265,669,366.09 yuan, compared to a positive 67,882,500.05 yuan in the same period last year[18] - Cash and cash equivalents at the end of the period were 249,160,346.16 yuan, down from 488,634,719.40 yuan at the end of the previous year[18] - The company's cash and cash equivalents decreased by 54.00% to ¥262,803,668.86, primarily due to reduced cash received from sales[5] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,339,277,978.64, a decrease of 2.53% from the end of the previous year[2] - The total current assets decreased to ¥884,870,039.81 from ¥992,404,613.46[11] - The total liabilities decreased to CNY 164,030,904.29 from CNY 210,610,507.00, showing improved financial health[13] - The equity attributable to shareholders of the parent company increased to CNY 1,175,247,074.35 from CNY 1,163,472,411.93, reflecting retained earnings growth[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,954[8] - The top three shareholders are Chen Zaihong (24.69%, 71,108,200 shares), Chen Yunqin (21.12%, 60,820,000 shares), and Chen Zaiwei (20.25%, 58,320,000 shares)[8] - The relationship among the top three shareholders indicates they are family members, jointly controlling the company[9] - The company has a total of 98,643,552 restricted shares held by executives, which are subject to lock-up agreements[10] - The company has no preferred shareholders or preferred shares outstanding[10] Operational Efficiency - Total operating costs for Q3 2024 were CNY 335,740,052.47, down from CNY 343,186,055.45, reflecting a cost reduction strategy[14] - The company reported a decrease in sales expenses to CNY 78,471,072.93 from CNY 92,293,397.97, indicating improved operational efficiency[14] - Research and development expenses rose by 41.65% to ¥38,881,143.78, driven by higher salaries for R&D personnel and increased outsourced R&D costs[5] - Research and development expenses increased to CNY 38,881,143.78, up from CNY 27,448,854.17, indicating a focus on innovation[14] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[15]